Search for other papers by Camille Galy-Bernadoy in
Google Scholar
PubMed
Search for other papers by Benjamin Lallemant in
Google Scholar
PubMed
Search for other papers by Guillaume Chambon in
Google Scholar
PubMed
Search for other papers by Huy Trang Pham in
Google Scholar
PubMed
Search for other papers by Christophe Reynaud in
Google Scholar
PubMed
Search for other papers by Caroline Alovisetti in
Google Scholar
PubMed
Search for other papers by Quentin Bonduelle in
Google Scholar
PubMed
Search for other papers by Anne Marie Guedj in
Google Scholar
PubMed
Search for other papers by Serge Lumbroso in
Google Scholar
PubMed
Search for other papers by David-Paul De Brauwere in
Google Scholar
PubMed
Introduction A total thyroidectomy is a common procedure, whose most frequent postoperative complication is hypoparathyroidism (hypoPTH). Medically, hypoPTH can cause disabling symptoms that may prove to be life-threatening [ 1 ]. Economically
Search for other papers by Emilie Sonne-Holm in
Google Scholar
PubMed
Search for other papers by Christoffer Holst Hahn in
Google Scholar
PubMed
Introduction One of the most common complications following total thyroidectomy is hypoparathyroidism [ 1 - 14 ] caused by devascularization or accidental resection of one or more of the parathyroid glands [ 15 ]. Hypoparathyroidism may be
Search for other papers by Luigino Dal Maso in
Google Scholar
PubMed
Search for other papers by Daniela Pierannunzio in
Google Scholar
PubMed
Search for other papers by Silvia Francisci in
Google Scholar
PubMed
Search for other papers by Angela De Paoli in
Google Scholar
PubMed
Search for other papers by Federica Toffolutti in
Google Scholar
PubMed
Search for other papers by Salvatore Vaccarella in
Google Scholar
PubMed
Search for other papers by Silvia Franceschi in
Google Scholar
PubMed
Search for other papers by Rossella Elisei in
Google Scholar
PubMed
Search for other papers by Ugo Fedeli in
Google Scholar
PubMed
Search for other papers by of the DEPTH Working Group in
Google Scholar
PubMed
Introduction Radioactive iodine (RAI) treatment may be used after total thyroidectomy (TT) for thyroid cancer for several purposes: remnant ablation to facilitate detection of recurrent disease, adjuvant treatment of subclinical residual tumor
Institute of Clinical Research, University of Southern Denmark, Odense, Denmark
Search for other papers by Lars Folkestad in
Google Scholar
PubMed
Search for other papers by Frans Brandt in
Google Scholar
PubMed
Search for other papers by Thomas Brix in
Google Scholar
PubMed
Search for other papers by Marianne Vogsen in
Google Scholar
PubMed
Search for other papers by Lars Bastholt in
Google Scholar
PubMed
Search for other papers by Peter Grupe in
Google Scholar
PubMed
Search for other papers by Jeanette Krogh Petersen in
Google Scholar
PubMed
Search for other papers by Laszlo Hegedüs in
Google Scholar
PubMed
patient had a total thyroidectomy, including removal of macro-pathologically suspected lymph nodes. Examination of resected specimens revealed a semi-lobulated mass measuring 40 × 20 × 25 mm (right lobe), 35 × 20 × 20 mm (left lobe), and an isthmus mass
Search for other papers by Chitra Choudhary in
Google Scholar
PubMed
Search for other papers by Leonard Wartofsky in
Google Scholar
PubMed
Search for other papers by Eshetu Tefera in
Google Scholar
PubMed
Search for other papers by Kenneth D. Burman in
Google Scholar
PubMed
Introduction Differentiated thyroid cancer patients are monitored for local or distant recurrence after total thyroidectomy. They typically undergo physical examination, serial measurement of serum thyroglobulin (Tg) levels, and serial
Search for other papers by Murat Faik Erdoğan in
Google Scholar
PubMed
Search for other papers by Özgür Demir in
Google Scholar
PubMed
Search for other papers by Reyhan Ünlü Ersoy in
Google Scholar
PubMed
Search for other papers by Kamile Gül in
Google Scholar
PubMed
Search for other papers by Berna İmge Aydoğan in
Google Scholar
PubMed
Search for other papers by Ziynet Alphan Üç in
Google Scholar
PubMed
Search for other papers by Türkan Mete in
Google Scholar
PubMed
Search for other papers by Sibel Ertek in
Google Scholar
PubMed
Search for other papers by Uğur Ünlütürk in
Google Scholar
PubMed
Search for other papers by Bekir Çakır in
Google Scholar
PubMed
Search for other papers by Yalçın Aral in
Google Scholar
PubMed
Search for other papers by Serdar Güler in
Google Scholar
PubMed
Search for other papers by Sevim Güllü in
Google Scholar
PubMed
Search for other papers by Demet Çorapçıoğlu in
Google Scholar
PubMed
Search for other papers by Selçuk Dağdelen in
Google Scholar
PubMed
Search for other papers by Gürbüz Erdoğan in
Google Scholar
PubMed
nerve compression [ 4 ]. Based on the above pathogenic model, thyroid disease could be responsible for the occurrence of GO; therefore, reduction of thyroid tissue either by radioiodine or total thyroidectomy (TTx) might deplete autoreactive T
Search for other papers by Shakeel Kautbally in
Google Scholar
PubMed
Search for other papers by Orsalia Alexopoulou in
Google Scholar
PubMed
Search for other papers by Chantal Daumerie in
Google Scholar
PubMed
Search for other papers by François Jamar in
Google Scholar
PubMed
Search for other papers by Michel Mourad in
Google Scholar
PubMed
Search for other papers by Dominique Maiter in
Google Scholar
PubMed
second-line treatments, at least in Europe, in case of unsuccessful therapy with antithyroid drugs (ATD), disease relapse, or drug intolerance [ 1 ]. Surgery should consist of a near total thyroidectomy (TTx), which leads to a reduced risk of relapse, as
Thyroid Diseases Center, Instituto Israelita de Ensino e Pesquisa Albert Einstein, São Paulo, Brazil
Search for other papers by Carolina C.P.S. Janovsky in
Google Scholar
PubMed
Thyroid Diseases Center, Instituto Israelita de Ensino e Pesquisa Albert Einstein, São Paulo, Brazil
Search for other papers by Rui M.B. Maciel in
Google Scholar
PubMed
Thyroid Diseases Center, Instituto Israelita de Ensino e Pesquisa Albert Einstein, São Paulo, Brazil
Search for other papers by Cleber P. Camacho in
Google Scholar
PubMed
Thyroid Diseases Center, Instituto Israelita de Ensino e Pesquisa Albert Einstein, São Paulo, Brazil
Search for other papers by Rosalia P. Padovani in
Google Scholar
PubMed
Thyroid Diseases Center, Instituto Israelita de Ensino e Pesquisa Albert Einstein, São Paulo, Brazil
Search for other papers by Claudia C. Nakabashi in
Google Scholar
PubMed
Thyroid Diseases Center, Instituto Israelita de Ensino e Pesquisa Albert Einstein, São Paulo, Brazil
Search for other papers by Ji H. Yang in
Google Scholar
PubMed
Thyroid Diseases Center, Instituto Israelita de Ensino e Pesquisa Albert Einstein, São Paulo, Brazil
Search for other papers by Eduardo Z. Malouf in
Google Scholar
PubMed
Thyroid Diseases Center, Instituto Israelita de Ensino e Pesquisa Albert Einstein, São Paulo, Brazil
Search for other papers by Elza S. Ikejiri in
Google Scholar
PubMed
Thyroid Diseases Center, Instituto Israelita de Ensino e Pesquisa Albert Einstein, São Paulo, Brazil
Search for other papers by M. Conceição O.C. Mamone in
Google Scholar
PubMed
Search for other papers by Jairo Wagner in
Google Scholar
PubMed
Thyroid Diseases Center, Instituto Israelita de Ensino e Pesquisa Albert Einstein, São Paulo, Brazil
Search for other papers by Danielle M. Andreoni in
Google Scholar
PubMed
Thyroid Diseases Center, Instituto Israelita de Ensino e Pesquisa Albert Einstein, São Paulo, Brazil
Search for other papers by Rosa Paula M. Biscolla in
Google Scholar
PubMed
follow-up care [ 2 , 7 , 8 ]. The treatment of differentiated thyroid cancer usually consists of total thyroidectomy (TT) and radioiodine remnant ablation (RRA) [ 4 , 8 ]. The rationale for the use of RRA comprises: remnant ablation, to facilitate the
Search for other papers by Amanda La Greca in
Google Scholar
PubMed
Search for other papers by Bin Xu in
Google Scholar
PubMed
Search for other papers by Ronald Ghossein in
Google Scholar
PubMed
Search for other papers by R. Michael Tuttle in
Google Scholar
PubMed
Search for other papers by Mona M. Sabra in
Google Scholar
PubMed
(includes more than 1 tumor focus sized ≥1 cm). Several studies have confirmed the risk of structural disease recurrence in multifocal papillary microcarcinoma treated with total thyroidectomy to be low, varying from 4 to 6% [ 4 , 5 , 6 ]. In similar
Search for other papers by Lara Gut in
Google Scholar
PubMed
Search for other papers by Selina Bernet in
Google Scholar
PubMed
Search for other papers by Monika Huembelin in
Google Scholar
PubMed
Search for other papers by Magdalena Mueller in
Google Scholar
PubMed
Search for other papers by Ciril Baechli in
Google Scholar
PubMed
Search for other papers by Daniel Koch in
Google Scholar
PubMed
Search for other papers by Christian Nebiker in
Google Scholar
PubMed
Search for other papers by Philipp Schuetz in
Google Scholar
PubMed
Search for other papers by Beat Mueller in
Google Scholar
PubMed
Search for other papers by Emanuel Christ in
Google Scholar
PubMed
University Center for Gastrointestinal and Liver Diseases, St. Clara Hospital and University Hospital, Basel, Switzerland
Search for other papers by Fahim Ebrahimi in
Google Scholar
PubMed
Division of Endocrinology, Diabetes, and Metabolism, University Hospital Basel, Basel, Switzerland
Search for other papers by Alexander Kutz in
Google Scholar
PubMed
]. Various factors determine clinical outcomes after thyroidectomy, including experience of the performing surgeon, size and procedural volume of the hospital, and quality of perioperative management [ 4 , 11 - 19 ]. Due to the extent of surgery, total